OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, ...
Spain: Researchers have found in a new study that sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a neutral effect on ...
In work that could someday improve treatments for epilepsy, scientists have the first three-dimensional structure of a member of a large family of human proteins that carry charged particles -- ions - ...
In patients without diabetes, sodium–glucose cotransporter-2 (SGLT2) inhibitors (or “flozins”) should be considered for moderate chronic kidney disease or clinical heart failure regardless of ejection ...
We thank Dr. Mithoowani and colleagues for their excellent review on the investigation and management of erythrocytosis,1 which provides a comprehensive overview and approach to a common presentation ...
The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high ...
About The Study: In this study of discharge prescription of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) among patients hospitalized for heart failure, prescription rates increased ...
Hosted on MSN
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 (HealthDay News) -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback